Paul Da Silva Jardine

Paul Da Silva Jardine is a venture partner at ATP. Paul spent 25 years at Pfizer Research, first as head of Cardiovascular and Metabolic Diseases (CVMD) Chemistry, then as vice president of the CVMD Biology Research Unit. Teams under Paul’s leadership discovered and developed more than 50 clinical candidates, two of which were licensed by the FDA and EMA as human medicines, and two of which were approved as veterinary medicines. In 2015, Paul left Pfizer to found and lead Staten Biotechnology, delivering into clinical development the only known anti-ApoC3 antibody for the treatment of coronary heart disease, which in 2018 Novo Nordisk acquired the option to buy for €430 million. Paul was a venture partner at ATP from 2017 to 2019, during which time he created a program that was incorporated into ATP portfolio company Chinook Therapeutics (NAS: KDNY). He then headed drug discovery efforts for Foresite Labs before returning to ATP.

Paul received a BS in chemistry from the University of Texas at Austin, and at Harvard University he earned a PhD and conducted postdoctoral research in synthetic organic chemistry in the labs of Nobel laureate chemist E.J. Corey.